menu
    • menu
    [{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TMB-365","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiMed Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TaiMed Biologics \/ Not Applicable"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"AcedrA BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ibalisumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiMed Biologics \/ AcedrA BioPharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"TaiMed Biologics \/ AcedrA BioPharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by TaiMed Biologics

    Menu

    TaiMed Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TaiMed Biologics

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalisumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : AcedrA BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            TaiMed Partners with AcedrA To Commercialize Trogarzo® in MENA Region

                            Details : AcedrA will register, promote, and commercialize Trogarzo (Ibalizumab-uiyk), a CD4-directed post-attachment HIV-1 inhibitor, for treating HIV-1 infection in the MENA region.

                            Brand Name : Trogarzo

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 18, 2024

                            Lead Product(s) : Ibalisumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : AcedrA BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TaiMed Biologics

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMB-365,TMB-380

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment

                            Details : TMB-365/380 monoclonal antibodies is an ultra-long-acting new drug combination, which is investigated for the treatment of human immunodeficiency virus infection.

                            Brand Name : TMB-365

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 16, 2023

                            Lead Product(s) : TMB-365,TMB-380

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth